Ann: Mesoblast Director Appointed to Strategic Advisory Role, page-106

Absolutely. Investing in biotech requires multidisciplinary skills in response to the exhortation to DYOR otherwise you're tracking the hype. To be honest the quality of responses to the shorters minions posts have been astounding on this stock. I've got a mixed science biomed background (but work elsewhere now for many years) so I can read a paper and weigh veracity, but the punter value on MSB threads on this site presented by informed & largely LTHs is top shelf.

As far as vested interests and shorting go, remember that MSB has
1. a massive retail investor presentation in the shareholder list
2. high turnover
3. a product in a technical space where FUD is dynamic lifter (suppressor?)

MSB is sweet, fat and juicy shorter plums until it breaks SOC paradigms across the chronic/acute inflammation disease space, and the contrarian view does trigger reappraisal and play a key role in moderating the hype, but shorter minions are running out of FUD.